A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TQA3038 Injection in Healthy Adult Subjects.
Latest Information Update: 08 Dec 2023
At a glance
- Drugs TQA-3038 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 03 Dec 2023 Status changed from not yet recruiting to recruiting.
- 20 Oct 2023 New trial record